‘Landmark’ study stresses urgent need to work collaboratively toward equity, diversity and inclusion in research, prevention and care
In Canada, we are in danger of failing the rapidly growing number of people living with dementia and their care partners if services and supports are not tailored to their unique needs, according to a new study released today by the Alzheimer Society of Canada.
When you participate in the IG Wealth Management Walk for Alzheimer's, you join thousands of Canadians who want to see a world without Alzheimer’s disease and other dementias.
Alzheimer Society of Canada and Brain Canada Foundation Announce KTE Accelerator Grant Recipients
This Saturday, September 30th, marks the third National Day for Truth and Reconciliation, honouring the lost children and the survivors of the residential school system, their families and communities. Read our statement on what the Alzheimer Society of Canada is doing on this day, and find links to related resources.
A program that claims to reverse Alzheimer’s disease is growing in popularity, despite lack of evidence that it works. Learn more about the Bredesen protocol and its claims.
Each application was reviewed by experts in the field of dementia research, as well as volunteers with lived experience of dementia, to ensure that the projects receiving funding have the potential to truly make a difference for people living with dementia and caregivers.
On July 17, 2023, American drug company Eli Lilly and Company released full results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease. Here’s what people in Canada might want to know about it.
[Updated] Your questions, answered: What should Canadians know about lecanemab’s full U.S. FDA approval?
On July 6, 2023, the United States Food and Drug Administration granted full approval to the drug lecanemab (brand name Leqembi). This drug aims to slow the progress of Alzheimer's disease. Health Canada began to review the drug in May 2023.